CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL

Inclusion Criteria: * Newly diagnosed, histologically confirmed the following pathology subtype according to WHO 2008 classification: peripheral T Cell Lymphoma, not otherwise specified, angioimmunoblastic T cell lymphoma, ALK-negative anaplastic large cell lymphoma, enteropathy associated T cell lymphoma, subcutaneous panniculitis like T cell lymphoma, and hepatosplenic T-cell lymphoma. * ≥ 16 years of age. * Performance status of 2 or less. * Has no history of malignancy. * Has radiologically measurable disease. * Life expectancy ≥6 months. * Voluntarily sign an informed consent. Exclusion Criteria: * Pathology subtype with NK/T cell lymphoma, ALK positive-ALCL. * Primary central nervous system (CNS) lymphoma. * Previous systemic chemotherapy or local therapy. * Has undergone hematopoietic stem-cell transplantation (HSCT). * Has active infectious disease requiring general antibiotics, anti-fungal or anti-virus therapy. * Has uncontrollable cardiocerebrovascular, coagulative, autoimmune, or serious infectious disease. * Echocardiography shows left ventricular ejection fraction (LVEF) ≤ 50%. * Inadequate renal, hepatic or bone marrow function * Active liver or biliary disease. * Has other uncontrollable medical condition that may interfere with their participation in the study. * Woman in pregnancy or lactation. * Patient is known to be positive for Human immunodeficiency virus (HIV) infection.